Novartis to launch Stalevo, anti-parkinson drug.
The company said that 50% of the patients who treated with Levo-dopa, which was developed in 1960s for the treatment of Parkinsonian disease experienced with a diminished therapeutic ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
